Sign In
Buy CHE
$444.11
+8.04 (+1.84%)
At Close: Jun 23, 2026
Aptus Capital Advisors LLC Buys 2,433 Shares of Chemed Co. (NYSE:CHE)
06:12pm, Wednesday, 15'th Dec 2021 Transcript Daily
Aptus Capital Advisors LLC lifted its stake in shares of Chemed Co. (NYSE:CHE) by 14.3% in the 3rd quarter, Holdings Channel reports. The fund owned 19,440 shares of the companys stock after acquiring an additional 2,433 shares during the quarter. Aptus Capital Advisors LLCs holdings in Chemed were worth $9,043,000 as of its most recent []
Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses
04:13pm, Tuesday, 14'th Dec 2021 Zacks Investment Research
Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.
Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm
03:20pm, Tuesday, 14'th Dec 2021 Zacks Investment Research
The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.
Edwards (EW) States Long-Term Strategy, Provides 2022 View
03:45pm, Monday, 13'th Dec 2021 Zacks Investment Research
Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.
Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test
01:19pm, Monday, 13'th Dec 2021 Zacks Investment Research
Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
01:18pm, Monday, 13'th Dec 2021 Zacks Investment Research
Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
09:59am, Monday, 13'th Dec 2021
Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.
Chemed Co. (NYSE:CHE) Shares Sold by Janney Montgomery Scott LLC
02:58pm, Sunday, 12'th Dec 2021 Transcript Daily
Janney Montgomery Scott LLC lowered its stake in shares of Chemed Co. (NYSE:CHE) by 8.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,652 shares of the companys stock after selling 2,308 shares during the period. Janney Montgomery Scott LLC owned 0.17% of Chemed worth []
Here's Why You Should Retain Baxter (BAX) Stock For Now
04:49pm, Tuesday, 07'th Dec 2021 Zacks Investment Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
HealthEquity (HQY) Q3 Earnings Beat, FY 2022 View Lowered
04:05pm, Tuesday, 07'th Dec 2021 Zacks Investment Research
HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust Interchange revenues in the third quarter of fiscal 2022.
Here's Why You Should Retain Tandem Diabetes (TNDM) for Now
12:44pm, Tuesday, 07'th Dec 2021 Zacks Investment Research
Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.
CVS Health (CVS) New Alliance to Boost Digital Transformation
12:43pm, Tuesday, 07'th Dec 2021 Zacks Investment Research
CVS Health's (CVS) collaboration with Microsoft will accelerate digital transformation and empower employees to provide more customized and affordable care.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
04:15pm, Monday, 06'th Dec 2021 Zacks Investment Research
Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.
BD's (BDX) Buyout of Venclose to Improve Patient Outcome
03:49pm, Monday, 06'th Dec 2021 Zacks Investment Research
BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
01:15pm, Monday, 06'th Dec 2021 Zacks Investment Research
Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.
